BofA Securities调整了对Hims and Hers (NYSE:HIMS)的展望，将目标价从20.00美元上调至23.00美元，并维持买入评级。这一调整是基于美国食品和药物管理局（FDA）最近宣布重新评估曾列入短缺清单的tirzepatide药物的可用性。 FDA在周五的一份法庭文件中表示，将重新考虑早前将tirzepatide从短缺清单中移除的决定。该机构还指出，在审查该活性成分的 ...

Leerink Partners维持礼来(NYSE: LLY)股票"跑赢大市"评级，目标价保持在$990.00不变。该公司在预期礼来第三季度业绩时调整了其财务模型。

In accepting the FDA’s motion, U.S. District Judge Mark Pittman put on hold a lawsuit filed by the Outsourcing Facilities ...

The UK Government has signed a collaboration agreement with Lilly, the pharmaceutical giant behind weight loss medication ...

These drugs work similarly but differ in dosage and specific indications (uses). Research suggests that tirzepatide is more ...

Mounjaro, the brand name for tirzepatide, is a drug that treats type 2 diabetes by lowering blood sugar levels. According to ...

All doses of the diabetes and weight management injectable tirzepatide (Mounjaro, Zepbound) were taken off the FDA's shortage ...

In this randomized controlled trial, in patients with both moderate-severe obstructive sleep apnea (OSA) and obesity, it was ...

BMO Capital Markets analyst Evan Seigerman called it “another positive indication” for Eli Lilly, whose top-selling diabetes ...

Nearly 250,000 people in England could access a weight loss injection on the NHS. Tirzepatide is prescribed for type 2 diabetes, but has been shown in clinical trials to be effective for weight loss.